Director Dealing

Alliance Pharma PLC
20 July 2023
 

 

20 July 2023


 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Director Dealing

 

Alliance Pharma plc (AIM: APH), the international healthcare group, has been notified that Jo LeCouilliard, the non-executive Chair of the Company, purchased 40,957 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 48.8 pence per share on 20th July 2023.

 

Following this transaction, (i) Jo LeCouilliard's total beneficial interest in the Company is 40,957 Ordinary Shares, representing 0.008% of the Company's issued share capital.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jo LeCouilliard

2

Reason for the notification

a)

Position/status

Non-executive Chair, PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma Plc

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 

 

 

GB0031030819

 

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

 

d)

Price(s) and volume(s)

Price(s)

Volume(s)

48.8

40,957

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

40,957 Ordinary Shares, bought at a price of 48.8 pence per share, totalling £ 19,987.02.

 

f)

Date of the transaction

20 July 2023

g)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com




Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff


alliancepharma@buchanan.uk.com




Numis Securities Limited (Nominated Adviser and Joint Broker)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah




Investec Bank plc (Joint Broker)

+ 44 (0)20 7597 5970

Patrick Robb / Maria Gomez de Olea


 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings